Search

Your search keyword '"Joong Won Park"' showing total 407 results

Search Constraints

Start Over You searched for: Author "Joong Won Park" Remove constraint Author: "Joong Won Park"
407 results on '"Joong Won Park"'

Search Results

1. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

2. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study

3. Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

4. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

5. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

6. A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment

8. Sorafenib combined with radiation therapy for advanced hepatocellular carcinoma with portal and hepatic vein invasion extending to the inferior vena cava: a complete response case according to modified RECIST criteria

9. Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

10. Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

11. Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma

12. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment

13. Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer

14. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.

15. Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?

16. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma

17. Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe

18. Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database

19. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma

20. Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

21. Epidemiology of liver cancer in South Korea

22. Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)

23. Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

24. Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

26. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

27. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

28. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

29. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

30. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

31. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

32. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

33. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

34. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

35. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

36. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

37. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

38. Supp Figure S1 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

40. Data from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

41. Data from Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

42. Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

43. Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

45. Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

46. Supplementary Tables from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

47. CCR Translation for This Article from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

49. Data from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

50. Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Catalog

Books, media, physical & digital resources